Foundation clinical trials.

Suppr

超能文献

作者信息

Cameron David

机构信息

NCRN Co-ordinating Centre, MacMillan House, Fairburn House, 71-75 Clarendon Road, Leeds LS2 9LN, UK.

出版信息

Breast Cancer Res. 2009;11 Suppl 3(Suppl 3):S23. doi: 10.1186/bcr2442. Epub 2009 Dec 18.

DOI:10.1186/bcr2442

PMID:20030875

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2797703/

Abstract

摘要

相似文献

Foundation clinical trials.

Breast Cancer Res. 2009;11 Suppl 3(Suppl 3):S23. doi: 10.1186/bcr2442. Epub 2009 Dec 18.

Optimal regimen for treatment-naive hormone receptor-positive HER-2 negative metastatic breast cancer.

Future Oncol. 2019 Jan;15(2):105-107. doi: 10.2217/fon-2018-0086. Epub 2018 Nov 28.

Triple negative breast cancer: breast cancer research in evolution.

Breast Dis. 2010;32(1-2):1-4. doi: 10.3233/BD-2010-0314.

New approaches for triple-negative breast cancer.

Oncology (Williston Park). 2012 Oct;26(10):916, 931, 935.

Template for reporting results of biomarker testing of specimens from patients with carcinoma of the breast.

Arch Pathol Lab Med. 2014 May;138(5):595-601. doi: 10.5858/arpa.2013-0566-CP. Epub 2013 Nov 15.

Triple-negative breast cancer in focus: from biology to novel therapeutics. Editorial.

Ann Oncol. 2012 Aug;23 Suppl 6:vi5-6. doi: 10.1093/annonc/mds186.

Different subtypes of metaplastic breast cancer might have different sensitivity to neoadjuvant chemotherapy.

J BUON. 2019 Sep-Oct;24(5):2205.

High-dose chemotherapy for triple negative breast cancer.

Ann Oncol. 2007 Jan;18(1):202-203. doi: 10.1093/annonc/mdl306. Epub 2006 Sep 13.

Molecular oncology and the neoadjuvant setting: the perfect blend for treatment personalization and clinical trial design.

J Natl Cancer Inst Monogr. 2011;2011(43):67-70. doi: 10.1093/jncimonographs/lgr029.

Novel targets for triple-negative breast cancer.

Clin Adv Hematol Oncol. 2011 Sep;9(9):678-80.

本文引用的文献

Breast cancer with synchronous metastases: trends in survival during a 14-year period.

J Clin Oncol. 2004 Aug 15;22(16):3302-8. doi: 10.1200/JCO.2004.08.095.

Efficacy and safety of Herceptin in women with metastatic breast cancer: results from pivotal clinical studies.

Anticancer Drugs. 2001 Dec;12 Suppl 4:S3-10. doi: 10.1097/00001813-200112004-00002.

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

N Engl J Med. 2001 Mar 15;344(11):783-92. doi: 10.1056/NEJM200103153441101.

Prognostic and predictive factors in breast cancer by immunohistochemical analysis.

Mod Pathol. 1998 Feb;11(2):155-68.

Adjuvant systemic therapy and survival after breast cancer.

N Engl J Med. 1994 Mar 24;330(12):805-10. doi: 10.1056/NEJM199403243301201.

Measurement and management of carcinoma of the breast.

Clin Radiol. 1982 Sep;33(5):481-93. doi: 10.1016/s0009-9260(82)80153-0.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验